Ozanimod approved for relapsing MS in Australia
18 August 2020
Ozanimod has been approved by the TGA for the treatment of adults with relapsing forms of MS in Australia.
Ozanimod has been approved by the TGA for the treatment of adults with relapsing forms of MS in Australia.
MS research in Australia received a major boost in funding, bringing the amount raised for life-changing MS research in 2020 to $10.5 million.
Australian researchers have identified a way to block an inflammatory pathway in the brain – the Kynurenine pathway (KP).
Two MS Research Australia funded research groups are investigating the role of messenger molecules and uncovering how genes increase the risk of ms.
New research from the International Progressive MS Alliance discovers a way nerve fibres protect themselves from damage.
Andrea’s mum was diagnosed with MS 15 years ago. Andrea is powering MS research with a regular donation to help us stop and reverse MS.
Thanks to you, we can look back on a fruitful and exciting year in MS research. Research almost entirely funded by generous people like you.
Exciting progress has been made in the MS Research Australia funded research projects. Here’s a fraction of the incredible work you have helped to achieve.
Researchers have engaged with the MS community in regional Australia to understand their perspectives on barriers to exercise participation and promotion.